



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

PATENT

In re Application of:

LIAT MINTZ

CASE NO: 28238

SERIAL NO: 10/659,782

GROUP ART UNIT: 1636

FILED: SEPTEMBER 11, 2003

EXAMINER: J. DUNSTON

FOR: COMPOSITIONS, REAGENTS AND
KITS FOR AND METHODS OF
DIAGNOSING, MONITORING AND
TREATING OBESITY AND/OR DIABETES

DECLARATION UNDER 37 C.F.R. § 1.132

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

I, Liat Mintz, declare that:

I am a citizen of Israel and reside at 2 Kulesa Court, East Brunswick,
New Jersey 08816.

I am the founder of DiaLean Ltd., an Israeli corporation.

I received a Ph.D. in Immunology and Cell Research from the Tel-Aviv
University, Tel-Aviv, Israel; an M.Sc. in Microbiology from the Tel-Aviv University,
Tel-Aviv, Israel; and a B.Sc. in Life Sciences from the Tel-Aviv University, Tel-
Aviv, Israel.

I am the Applicant of the above-identified application.

The following are my remarks:

1. The Office Action indicated that claims 31-34 and 47-48 were rejected under 35 U.S.C. § 101 because the claimed invention is not supported by either a specific and substantial asserted utility or a well-established utility.
2. The Examiner asserted that "it is not clear whether the Ghrelin Variant 2 protein [SEQ ID NO:32] is intended to act as agonist or antagonist of physiological pathways related to diabetes and/or obesity. Further, there is no art

Considered
11/7/05
GD